IO Biotech Operating Income

The latest operating income for IOBT is $-92M as of September 2025. That compares with $-96M in the prior-year period — up 4.5% year over year. Investors often review this figure alongside IO Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, IOBT's operating income moved from $-96M to $-92M — a 4.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in IO Biotech's operating scale or balance-sheet position.

A operating income figure of $-92M for IOBT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting IOBT's operating income ($-92M), review year-over-year change from $-96M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.